JP2006517201A5 - - Google Patents

Download PDF

Info

Publication number
JP2006517201A5
JP2006517201A5 JP2006500277A JP2006500277A JP2006517201A5 JP 2006517201 A5 JP2006517201 A5 JP 2006517201A5 JP 2006500277 A JP2006500277 A JP 2006500277A JP 2006500277 A JP2006500277 A JP 2006500277A JP 2006517201 A5 JP2006517201 A5 JP 2006517201A5
Authority
JP
Japan
Prior art keywords
alkylenyl
alkyl
membered
independently
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006500277A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006517201A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2004/000023 external-priority patent/WO2004064842A1/en
Publication of JP2006517201A publication Critical patent/JP2006517201A/ja
Publication of JP2006517201A5 publication Critical patent/JP2006517201A5/ja
Pending legal-status Critical Current

Links

JP2006500277A 2003-01-17 2004-01-06 アミド及びエステルマトリックスメタロプロテアーゼ阻害剤 Pending JP2006517201A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44083703P 2003-01-17 2003-01-17
PCT/IB2004/000023 WO2004064842A1 (en) 2003-01-17 2004-01-06 Amide and ester matrix metalloproteinase inhibitors

Publications (2)

Publication Number Publication Date
JP2006517201A JP2006517201A (ja) 2006-07-20
JP2006517201A5 true JP2006517201A5 (enExample) 2006-12-21

Family

ID=32771869

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006500277A Pending JP2006517201A (ja) 2003-01-17 2004-01-06 アミド及びエステルマトリックスメタロプロテアーゼ阻害剤

Country Status (7)

Country Link
US (1) US20040142950A1 (enExample)
EP (1) EP1587516A1 (enExample)
JP (1) JP2006517201A (enExample)
BR (1) BRPI0406823A (enExample)
CA (1) CA2513115A1 (enExample)
MX (1) MXPA05007607A (enExample)
WO (1) WO2004064842A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
PA8578101A1 (es) * 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
CA2572324A1 (en) * 2003-07-02 2005-01-13 Warner-Lambert Company Llc Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
WO2005016926A1 (en) * 2003-08-19 2005-02-24 Warner-Lambert Company Llc Pyrido [3,4-d] pyrimidine derivatives as matrix metalloproteinase-13 inhibitors
MX2007014114A (es) 2005-05-10 2008-03-14 Intermune Inc Derivados de piridona para modular el sistema de proteina cinasa activada por estres.
CN101522676A (zh) * 2006-10-05 2009-09-02 Cv医药有限公司 用作硬脂酰-CoA脱氢酶抑制剂的双环含氮杂环化合物
WO2008076916A2 (en) * 2006-12-15 2008-06-26 Molecular Devices Corporation Thallium-sensitive agents and methods of using the same
US20080255161A1 (en) * 2007-04-11 2008-10-16 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
US20090105283A1 (en) * 2007-04-11 2009-04-23 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
JP5627574B2 (ja) * 2008-06-03 2014-11-19 インターミューン， インコーポレイテッド 炎症性および線維性疾患を治療するための化合物および方法
CA2740389A1 (en) * 2008-10-15 2010-05-20 Gilead Sciences, Inc. 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors
US20100267752A1 (en) * 2008-10-15 2010-10-21 Gilead Palo Alto, Inc. 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
GB201317286D0 (en) 2013-09-30 2013-11-13 Calscience Internat Ltd Composition and Use
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
GB201410407D0 (en) * 2014-06-11 2014-07-23 Univ Dundee And Syngene Internat Ltd Plc And Consejo Superior De Investigaciones Cientificas And Med Treatment of chagas disease
ES2896400T3 (es) 2014-08-01 2022-02-24 Nuevolution As Compuestos activos frente a bromdominios
GB201502268D0 (en) 2015-02-11 2015-04-01 Calscience Internat Ltd Dental composition and use
CN109776434B (zh) * 2019-03-20 2022-01-28 中南大学 3-苄基-6-酰氨基-2,4-(1h,3h)-喹唑啉二酮衍生物及其合成方法和用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385894A (en) * 1991-03-06 1995-01-31 Merck & Co., Inc. Disubstituted 6-aminoquinazolinones
US6008243A (en) * 1996-10-24 1999-12-28 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
JP2002536447A (ja) * 1999-02-12 2002-10-29 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー フェニル尿素およびフェニルチオ尿素誘導体
WO2001004103A1 (en) * 1999-07-13 2001-01-18 F. Hoffmann-La Roche Ag Benzazepinones and quinazolines
PA8539501A1 (es) * 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
DOP2002000334A (es) * 2001-02-14 2002-08-30 Warner Lambert Co Pirimidinas biciclicas como inhibidores de metaloproteinasas de matriz
JP2004518723A (ja) * 2001-02-14 2004-06-24 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー ピリミジンマトリックスメタロプロテイナーゼ阻害剤
WO2002064598A1 (en) * 2001-02-14 2002-08-22 Warner-Lambert Company Llc Thieno'2,3-d pyrimidindione derivatives as matrix metalloproteinase inhibitors
WO2002064578A1 (en) * 2001-02-14 2002-08-22 Warner-Lambert Company Llc Benzo thiadiazine matrix metalloproteinase inhibitors
PA8539401A1 (es) * 2001-02-14 2002-10-28 Warner Lambert Co Quinazolinas como inhibidores de mmp-13
PA8539301A1 (es) * 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz
DOP2002000333A (es) * 2001-02-14 2002-09-30 Warner Lambert Co Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
DOP2002000332A (es) * 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
US6924276B2 (en) * 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
WO2003032999A1 (en) * 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkyne matrix metalloproteinase inhibitors
US6962922B2 (en) * 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
US6894057B2 (en) * 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
US6747147B2 (en) * 2002-03-08 2004-06-08 Warner-Lambert Company Oxo-azabicyclic compounds
US20040006077A1 (en) * 2002-06-25 2004-01-08 Bernard Gaudilliere Thiazine and oxazine derivatives as MMP-13 inhibitors
WO2004014921A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc 5,6-fused uracil derivatives as matrix metalloproteinase inhibitors
JP2006503008A (ja) * 2002-08-13 2006-01-26 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー マトリクスメタロプロテイナーゼ阻害物質としての４−ヒドロキシキノリン誘導体
AU2003249534A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors
AU2003250469A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Isoquinoline derivatives as matrix metalloproteinase inhibitors
MXPA05001786A (es) * 2002-08-13 2005-04-25 Warner Lambert Co Derivados de azaisoquinolina como inhibidores de la metaloproteinasa de matriz.
AU2003250475A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 5,6-fused 3,4-dihydropyrimidine-2-one derivatives as matrix metalloproteinase inhibitors
AU2003253149A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 3,4-dihydroquinolin-2-one, 5,6-fused oxazin-3-one, and 5,6-fused thiazin-3-one derivatives as matrix metalloproteinase inhibitors
AU2003250482A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Phthalimide derivatives as matrix metalloproteinase inhibitors
WO2004014909A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
AU2003249535A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 1,6-fused uracil derivatives as matrix metalloproteinase inhibitors
AU2003253150A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Chromone derivatives as matrix metalloproteinase inhibitors
PA8578101A1 (es) * 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
WO2004014923A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
WO2004014384A2 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
WO2004014892A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Monocyclic derivatives as matrix metalloproteinase inhibitors
AU2003253165A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
AU2003249540A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
AU2003249477A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
AU2003250466A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
JP2006500351A (ja) * 2002-08-13 2006-01-05 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー マトリックスメタロプロテアーゼ−１３阻害剤としてのピリミジン−２，４−ジオン誘導体

Similar Documents

Publication Publication Date Title
JP2014524441A5 (enExample)
JP2014528466A5 (enExample)
JP2004516314A5 (enExample)
JP2010511721A5 (enExample)
JP2011528654A5 (enExample)
JP2018535967A5 (enExample)
JP2010501478A5 (enExample)
JP2012510523A5 (enExample)
JP2008525416A5 (enExample)
JP2008533191A5 (enExample)
JP2009536221A5 (enExample)
JP2012505871A5 (enExample)
JP2006507355A5 (enExample)
JP2005523922A5 (enExample)
JP2005530811A5 (enExample)
JP2002526458A5 (enExample)
JP2013512915A5 (enExample)
JP2007534702A5 (enExample)
JP2004525888A5 (enExample)
JP2004502756A5 (enExample)
JP2019500315A5 (enExample)
JP2010520851A5 (enExample)
JP2002525323A5 (enExample)
JP2009520695A5 (enExample)
BRPI0514386B8 (pt) bis (metanossulfonato) de n-hidróxi-4-{5-[4-(5-isopropil-2-metil-1,3-triazol-4-il)fenóxi]pentóxi}benzamidina, método para preparar os mesmos, suas composições farmacêuticas e formulações orais